Company’s 36-month beta value is 1.13.Analysts have differing opinions on the stock, with 3 analysts rating it as a “buy,” 2 as “overweight,” 3 as “hold,” and 0 as “sell.”
The public float for ALXO is 34.04M, and currently, short sellers hold a 17.29% ratio of that floaft. The average trading volume of ALXO on March 21, 2025 was 1.11M shares.
ALXO) stock’s latest price update
The stock price of Alx Oncology Holdings Inc (NASDAQ: ALXO) has dropped by -6.04 compared to previous close of 0.75. Despite this, the company has seen a fall of -15.28% in its stock price over the last five trading days. zacks.com reported 2025-03-20 that ALX Oncology Holdings (ALXO) appears to have found support after losing some value lately, as indicated by the formation of a hammer chart. In addition to this technical chart pattern, strong agreement among Wall Street analysts in revising earnings estimates higher enhances the stock’s potential for a turnaround in the near term.
ALXO’s Market Performance
Alx Oncology Holdings Inc (ALXO) has experienced a -15.28% fall in stock performance for the past week, with a -37.21% drop in the past month, and a -60.71% drop in the past quarter. The volatility ratio for the week is 7.68%, and the volatility levels for the past 30 days are at 11.63% for ALXO. The simple moving average for the past 20 days is -26.07% for ALXO’s stock, with a -73.98% simple moving average for the past 200 days.
Analysts’ Opinion of ALXO
Many brokerage firms have already submitted their reports for ALXO stocks, with Jefferies repeating the rating for ALXO by listing it as a “Buy.” The predicted price for ALXO in the upcoming period, according to Jefferies is $3 based on the research report published on March 06, 2025 of the current year 2025.
Jefferies, on the other hand, stated in their research note that they expect to see ALXO reach a price target of $2, previously predicting the price at $12. The rating they have provided for ALXO stocks is “Hold” according to the report published on December 19th, 2024.
Stifel gave a rating of “Hold” to ALXO, setting the target price at $14 in the report published on March 08th of the previous year.
ALXO Trading at -42.27% from the 50-Day Moving Average
After a stumble in the market that brought ALXO to its low price for the period of the last 52 weeks, the company was unable to rebound, for now settling with -96.05% of loss for the given period.
Volatility was left at 11.63%, however, over the last 30 days, the volatility rate increased by 7.68%, as shares sank -37.03% for the moving average over the last 20 days. Over the last 50 days, in opposition, the stock is trading -62.08% lower at present.
During the last 5 trading sessions, ALXO fell by -15.03%, which changed the moving average for the period of 200-days by -92.13% in comparison to the 20-day moving average, which settled at $0.9514. In addition, Alx Oncology Holdings Inc saw -57.89% in overturn over a single year, with a tendency to cut further losses.
Insider Trading
Reports are indicating that there were more than several insider trading activities at ALXO starting from Pinto Shelly, who sale 550 shares at the price of $1.15 back on Feb 19 ’25. After this action, Pinto Shelly now owns 87,352 shares of Alx Oncology Holdings Inc, valued at $633 using the latest closing price.
Pons Jaume, the PRESIDENT & CSO of Alx Oncology Holdings Inc, sale 1,326 shares at $1.15 during a trade that took place back on Feb 19 ’25, which means that Pons Jaume is holding 579,388 shares at $1,525 based on the most recent closing price.
Stock Fundamentals for ALXO
The total capital return value is set at -1.1. Equity return is now at value -88.91, with -69.10 for asset returns.
Based on Alx Oncology Holdings Inc (ALXO), the company’s capital structure generated 0.08 points at debt to capital in total, while cash flow to debt ratio is standing at -12.31. The debt to equity ratio resting at 0.09. The interest coverage ratio of the stock is -82.4.
Currently, EBITDA for the company is -132.25 million with net debt to EBITDA at 0.06. The liquidity ratio also appears to be rather interesting for investors as it stands at 7.26.
Conclusion
In a nutshell, Alx Oncology Holdings Inc (ALXO) has experienced a bad performance in recent times. The stock has received mixed “buy” and “hold” ratings from analysts. It’s important to note that the stock is currently trading at a significant distance from its 50-day moving average and its 52-week high.
